Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer

British Journal of Cancer

Volumn 114, Issue 1, 2016, Pages 30-36

  Loupakis, Fotios ^a   Moretto, Roberto ^a   Aprile, Giuseppe ^b   Muntoni, Marta ^a   Cremolini, Chiara ^a   Iacono, Donatella ^b   Casagrande, Mariaelena ^b   Ferrari, Laura ^b   Salvatore, Lisa ^a   Schirripa, Marta ^a   Rossini, Daniele ^a   De Maglio, Giovanna ^b   Fasola, Gianpiero ^b   Calvetti, Lorenzo ^c   Pilotto, Sara ^c   Carbognin, Luisa ^c   Fontanini, Gabriella ^d   Tortora, Giampaolo ^c   Falcone, Alfredo ^a   Sperduti, Isabella ^e   Bria, Emilio ^c   more..

^a UNIVERSITY HOSPITAL OF PISA   (Italy)

^b SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

^c UNIVERSITY HOSPITAL OF VERONA   (Italy)

^d UNIVERSITY OF PISA   (Italy)

^e REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

BRAF; metastatic colorectal cancer; nomogram

Indexed keywords

ADULT; AGED; ARTICLE; BRAF GENE; CANCER PATIENT; EXTERNAL VALIDITY; FEMALE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; INTERNAL VALIDITY; MAJOR CLINICAL STUDY; MALE; MEASUREMENT ACCURACY; METASTATIC COLORECTAL CANCER; NOMOGRAM; ONCOGENE; ONCOGENE RAS; PREDICTIVE VALUE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; COLORECTAL TUMOR; GENETICS; METASTASIS; MIDDLE AGED; MORTALITY; MUTATION; PATHOLOGY; VERY ELDERLY;

B RAF KINASE; BRAF PROTEIN, HUMAN;

ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; FEMALE; GENES, RAS; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; NOMOGRAMS; PROTO-ONCOGENE PROTEINS B-RAF; RETROSPECTIVE STUDIES;

EID: 84954393384     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2015.399     Document Type: Article

References (32)

1. Atreya CE, Corcoran RB, Kopetz S. (2015). Expanded RAS: Refining the Patient Population. J Clin Oncol. 33(7): 682-685.
2. Clancy C, Burke JP, Kalady MF, Coffey JC. (2013). BRAF mutation is associated with distinct clinicopathological characteristics in colorectal cancer: a systematic review and meta-Analysis. Colorectal Dis. 15(12): e711-e718.
3. Clinical Practice Guidelines in Oncology (NCCN Guidelines). (2015). Colon Cancer. Version 2. NCCN.org
4. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA. (2002). Mutations of the BRAF gene in human cancer. Nature. 417(6892): 949-954.
5. de Gramont A, Haller DG, Sargent DJ, Tabernero J, Matheson A, Schilsky RL. (2010). Toward efficient trials in colorectal cancer: the ARCAD Clinical Trials Program. J Clin Oncol. 28(4): 527-530.
6. De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, Kalogeras KT, Kotoula V, Papamichael D, Laurent-Puig P, Penault-Llorca F, Rougier P, Vincenzi B, Santini D, Tonini G, Cappuzzo F, Frattini M, Molinari F, Saletti P, De Dosso S, Martini M, Bardelli A, Siena S, Sartore-Bianchi A, Tabernero J, Macarulla T, Di Fiore F, Gangloff AO, Ciardiello F, Pfeiffer P, Qvortrup C, Hansen TP, Van Cutsem E, Piessevaux H, Lambrechts D, Delorenzi M, Tejpar S. (2010). Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 11(8): 753-762.
7. Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A. (2008). Wild-Type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol. 26(35): 5705-5712.
8. Goldstein J, Tran B, Ensor J, Gibbs P, Wong HL, Wong SF, Vilar E, Tie J, Broaddus R, Kopetz S, Desai J, Overman MJ. (2014). Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H). Ann Oncol. 25(5): 1032-1038.
9. Gonsalves WI, Mahoney MR, Sargent DJ, Nelson GD, Alberts SR, Sinicrope FA, Goldberg RM, Limburg PJ, Thibodeau SN, Grothey A, Hubbard JM, Chan E, Nair S, Berenberg JL, McWilliams RR. Alliance for Clinical Trials in O. (2014). Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147. J Natl Cancer Inst. 106(7): 1-8.
10. Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmuller C, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Hielscher J, Scholz M, Muller S, Link H, Niederle N, Rost A, Hoffkes HG, Moehler M, Lindig RU, Modest DP, Rossius L, Kirchner T, Jung A, Stintzing S. (2014). FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 15(10): 1065-1075.
11. Iasonos A, Schrag D, Raj GV, Panageas KS. (2008). How to build and interpret a nomogram for cancer prognosis. J Clin Oncol. 26(8): 1364-1370.
12. Laurent-Puig P, Cayre A, Manceau G, Buc E, Bachet JB, Lecomte T, Rougier P, Lievre A, Landi B, Boige V, Ducreux M, Ychou M, Bibeau F, Bouche O, Reid J, Stone S, Penault-Llorca F. (2009). Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-Type KRAS metastatic colon cancer. J Clin Oncol. 27(35): 5924-5930.
13. Lenz H, Niedzwiecki D, Innocenti F, Blanke C, Mahony M, O?Neil B, Shaw J, Polite B, Hochster H, Atkins J, Goldberg R, Mayer R, Schilsky R, Bertagnolli M, Venook A. (2014). CALGB/SWOG 80405: phase III trial of irinotecan/5-FU/ Leucovorin (FOLFIRI) or Oxaliplatin/5-FU/Leucovorin (MFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (PTS) with expanded ras analyses untreated metastatic adenocarcinoma of the colon or rectum (MCRC). Ann Oncol. 25(Suppl. 5): v1-v41.
14. Lieu CH, Renfro LA, de Gramont A, Meyers JP, Maughan TS, Seymour MT, Saltz L, Goldberg RM, Sargent DJ, Eckhardt SG, Eng C. Aide et Recherche en Cancerologie Digestive F. (2014). Association of age with survival in patients with metastatic colorectal cancer: analysis from the ARCAD Clinical Trials Program. J Clin Oncol. 32(27): 2975-2984.
15. Loupakis F, Cremolini C, Masi G, Lonardi S, Zagonel V, Salvatore L, Cortesi E, Tomasello G, Ronzoni M, Spadi R, Zaniboni A, Tonini G, Buonadonna A, Amoroso D, Chiara S, Carlomagno C, Boni C, Allegrini G, Boni L, Falcone A. (2014). Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med. 371(17): 1609-1618.
16. Loupakis F, Ruzzo A, Cremolini C, Vincenzi B, Salvatore L, Santini D, Masi G, Stasi I, Canestrari E, Rulli E, Floriani I, Bencardino K, Galluccio N, Catalano V, Tonini G, Magnani M, Fontanini G, Basolo F, Falcone A, Graziano F. (2009). KRAS codon. 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wildtype metastatic colorectal cancer. Br J Cancer. 101(4): 715-721.
17. Peeters M, Oliner KS, Parker A, Siena S, Van Cutsem E, Huang J, Humblet Y, Van Laethem JL, Andre T, Wiezorek J, Reese D, Patterson SD. (2013). Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer. Clin Cancer Res. 19(7): 1902-1912.
18. Popovici V, Budinska E, Tejpar S, Weinrich S, Estrella H, Hodgson G, Van Cutsem E, Xie T, Bosman FT, Roth AD, Delorenzi M. (2012). Identification of a poor-prognosis BRAF-mutant-like population of patients with colon cancer. J Clin Oncol. 30(12): 1288-1295.
19. Richman SD, Seymour MT, Chambers P, Elliott F, Daly CL, Meade AM, Taylor G, Barrett JH, Quirke P. (2009). KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol. 27(35): 5931-5937.
20. Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D, Dietrich D, Biesmans B, Bodoky G, Barone C, Aranda E, Nordlinger B, Cisar L, Labianca R, Cunningham D, Van Cutsem E, Bosman F. (2010). Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol. 28(3): 466-474.
21. Samowitz WS, Albertsen H, Sweeney C, Herrick J, Caan BJ, Anderson KE, Wolff RK, Slattery ML. (2006). Association of smoking, CpG island methylator phenotype, and V600E BRAF mutations in colon cancer. J Natl Cancer Inst. 98(23): 1731-1738.
22. Saridaki Z, Papadatos-Pastos D, Tzardi M, Mavroudis D, Bairaktari E, Arvanity H, Stathopoulos E, Georgoulias V, Souglakos J. (2010). BRAF mutations, microsatellite instability status and cyclin D1 expression predict metastatic colorectal patients? outcome. Br J Cancer. 102(12): 1762-1768.
23. Saridaki Z, Tzardi M, Sfakianaki M, Papadaki C, Voutsina A, Kalykaki A, Messaritakis I, Mpananis K, Mavroudis D, Stathopoulos E, Georgoulias V, Souglakos J. (2013). BRAFV600E mutation analysis in patients with metastatic colorectal cancer (mCRC) in daily clinical practice: correlations with clinical characteristics, and its impact on patients? outcome. PLoS One. 8(12): e84604.
24. Schirripa M, Cremolini C, Loupakis F, Morvillo M, Bergamo F, Zoratto F, Salvatore L, Antoniotti C, Marmorino F, Sensi E, Lupi C, Fontanini G, De Gregorio V, Giannini R, Basolo F, Masi G, Falcone A. (2015). Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer. Int J Cancer. 136(1): 83-90.
25. Shuster JJ. (1991). Median follow-up in clinical trials. J Clin Oncol. 9(1): 191-192.
26. Simon RM, Paik S, Hayes DF. (2009). Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst. 101(21): 1446-1452.
27. Souglakos J, Philips J, Wang R, Marwah S, Silver M, Tzardi M, Silver J, Ogino S, Hooshmand S, Kwak E, Freed E, Meyerhardt JA, Saridaki Z, Georgoulias V, Finkelstein D, Fuchs CS, Kulke MH, Shivdasani RA. (2009). Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer. Br J Cancer. 101(3): 465-472.
28. Tie J, Gibbs P, Lipton L, Christie M, Jorissen RN, Burgess AW, Croxford M, Jones I, Langland R, Kosmider S, McKay D, Bollag G, Nolop K, Sieber OM, Desai J. (2011). Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAF(V600E) mutation. Int J Cancer. 128(9): 2075-2084.
29. Tran B, Kopetz S, Tie J, Gibbs P, Jiang ZQ, Lieu CH, Agarwal A, Maru DM, Sieber O, Desai J. (2011). Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer. 117(20): 4623-4632.
30. Van Cutsem E, Cervantes A, Nordlinger B, Arnold D. (2014). Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 25(Suppl. 3): iii1-iii9.
31. Yaeger R, Cercek A, Chou JF, Sylvester BE, Kemeny NE, Hechtman JF, Ladanyi M, Rosen N, Weiser MR, Capanu M, Solit DB, Dangelica MI, Vakiani E, Saltz LB. (2014). BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer. Cancer. 120(15): 2316-2324.
32. Yokota T, Ura T, Shibata N, Takahari D, Shitara K, Nomura M, Kondo C, Mizota A, Utsunomiya S, Muro K, Yatabe Y. (2011). BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer. Br J Cancer. 104(5): 856-862.